Завод ДИОД DIOD

Quarterly report 2025-Q4
added 08-10-2026

Завод ДИОД Income Statement 2025-2007 | DIOD

Brief overview of financial results at Завод ДИОД

The comparison covers a five-year financial horizon. Revenue reported by Завод ДИОД was 517 million rubles at the beginning of the period and 521 million rubles at the end. The cumulative result was +0.9%, corresponding to roughly 0.2% per year. Revenue was effectively stagnant over the period.

The operating result measured by EBITDA moved from 77.2 million rubles to −28 million rubles, or −136.2%. EBITDA underperformed the top-line trend. EBITDA margin moved from 15% to −5.4%. A lower EBITDA share weakens the quality of the result.

Net income moved from 37.2 thousand rubles at the start to −71 million rubles at the end. The move from profit to loss indicates a material deterioration in final efficiency.

Market capitalization changed from 684 million rubles to 950 million rubles (+38.9%). The share-price trend was broadly consistent with improving results.

What the figures show

Signs of deterioration dominate the five-year picture. The main areas of concern are a low EBITDA margin, a softer top-line trend and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Завод ДИОД

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	521 M	511 M	549 M	561 M	602 M	517 M	658 M	774 M	825 M	886 M	964 M	1.28 B	1.14 B	1.15 B	1.55 B	1.55 B	1.56 B	1.73 B	1.62 B
Cost Of Revenue	-	-	255 M	242 M	245 M	192 M	300 M	329 M	411 M	485 M	316 M	583 M	400 M	460 M	711 M	752 M	726 M	674 M	677 M
Gross Profit	-	-	294 M	319 M	357 M	325 M	358 M	446 M	414 M	401 M	649 M	700 M	737 M	691 M	839 M	796 M	833 M	1.06 B	947 M
Gross Profit Ratio	-	-	0.54	0.57	0.59	0.63	0.54	0.58	0.5	0.45	0.67	0.55	0.65	0.6	0.54	0.51	0.53	0.61	0.58
General and Administrative Expenses	272 M	246 M	162 M	29.8 M	23.2 M	19.7 M	27.3 M	136 M	37.4 M	50.7 M	28.2 M	23.8 M	164 M	27.4 M	156 M	150 M	160 M	154 M	-
Selling And Marketing Expenses	-	-	122 M	68.6 M	96.7 M	97.5 M	125 M	195 M	262 M	122 M	336 M	286 M	390 M	286 M	383 M	332 M	369 M	516 M	-
Selling General And Administrative Expenses	-	-	293 M	98.3 M	120 M	117 M	153 M	371 M	300 M	173 M	364 M	310 M	553 M	314 M	539 M	482 M	529 M	670 M	538 M
Other Expenses	-	-	-690 K	175 M	141 M	132 M	134 M	18.2 M	-37.3 M	4.17 M	-24.6 M	193 M	-207 M	-11 M	-52.5 M	-46.8 M	-236 M	-88.5 M	57.8 M
Operating Expenses	299 M	284 M	292 M	274 M	261 M	249 M	286 M	389 M	467 M	362 M	572 M	517 M	554 M	533 M	549 M	493 M	310 M	599 M	614 M
Cost And Expenses	-	-	547 M	516 M	507 M	441 M	586 M	718 M	879 M	847 M	888 M	1.1 B	954 M	992 M	1.26 B	1.25 B	1.04 B	1.27 B	-1.29 B
Interest Expense	-	-	-	37 K	19 K	576 K	3.52 M	-	23.5 M	37.2 M	112 M	94.4 M	99.8 M	97.9 M	89.6 M	93.6 M	116 M	44.1 M	2.02 M
Depreciation And Amortization	-	-	20.6 M	5.24 M	15.9 M	18.5 M	18.1 M	29.9 M	26.5 M	28.6 M	6.54 M	9.73 M	-206 M	4.6 M	-51.1 M	-44 M	2.2 M	-4.54 M	20.5 M
EBITDA	-28 M	-266 M	22.4 M	65.2 M	131 M	77.2 M	109 M	90.4 M	35.7 M	-66.2 M	12.6 M	185 M	6.28 M	151 M	251 M	259 M	570 M	452 M	357 M
EBITDA Ratio	-0.05	-0.52	0.04	0.12	0.2	0.16	0.16	0.12	-0.08	-0.01	-0.17	0.14	-0.02	0.13	0.15	0.17	0.34	0.26	0.22
Operating Income	-39 M	-286 M	1.82 M	45.2 M	107 M	73.2 M	99.2 M	56.4 M	-46.5 M	49.5 M	91.9 M	184 M	183 M	163 M	291 M	303 M	523 M	457 M	333 M
Operating Income Ratio	-0.07	-0.56	0.0	0.08	0.18	0.14	0.15	0.07	-0.06	0.06	0.1	0.14	0.16	0.14	0.19	0.2	0.34	0.26	0.21
Income Before Tax	-71 M	-248 M	13.4 M	60 M	115 M	57.1 M	80.8 M	46.7 M	-26.9 M	-134 M	-106 M	81.1 M	-137 M	25.1 M	150 M	165 M	410 M	408 M	335 M
Income Before Tax Ratio	-	-	0.02	0.11	0.19	0.11	0.12	60.4	-0.03	-0.15	-0.11	0.06	-0.12	0.02	0.1	0.11	0.26	0.24	0.21
Income Tax Expense	-	-	4.98 M	17.6 M	26.1 M	22.3 M	15.5 M	36.5 M	-10.6 M	6.88 M	13.3 M	22.8 M	20.2 M	17.2 M	37.8 M	35.4 M	45.8 M	106 M	101 M
Net Income Ratio	-0.14	-0.48	0.02	0.07	0.15	0.07	0.1	0.01	-0.03	-0.16	-0.12	0.04	-0.14	0.01	0.08	0.11	0.24	0.17	0.14
Earnings Per Share, EPS	-0.78	-3	0.09	0.44	0.99	0.38	0.7	0.12	-0.29	-1.54	-1.31	0.63	-1.71	0.15	1.4	1.78	4.08	33.1 K	50 K
EPS Diluted	-0.78	-3	0.09	0.44	0.99	0.38	0.7	0.12	-0.29	-1.54	-1.31	0.63	-1.71	0.15	1.4	1.78	4.08	33.1 K	-
Weighted Average Shares Outstanding	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	98 M	92 M	91.5 M	90.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	9.15 K	9.15 K

All numbers in RUB currency

Quarterly Income Statement Завод ДИОД

	2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Revenue	254 M	267 M	255 M	256 M	274 M	260 K	301 M	294 M	309 M	299 M	218 M	322 M	336 M	385 M	389 M	370 M	455 M	413 M	473 M	549 M	415 M	642 M	642 M	638 M	249 M	775 M	775 M	774 M	774 M	779 M	779 M	865 M	865 M
Cost Of Revenue	-	-	-	-	127 M	118 K	131 M	138 M	113 M	114 M	78.1 M	115 M	189 M	171 M	157 M	193 M	218 M	228 M	258 M	229 M	138 M	291 M	291 M	233 M	83.6 M	356 M	356 M	376 M	376 M	363 M	363 M	337 M	337 M
Gross Profit	-	-	-	-	147 M	142 K	171 M	156 M	195 M	185 M	140 M	206 M	147 M	214 M	232 M	177 M	237 M	185 M	215 M	320 M	278 M	350 M	350 M	405 M	166 M	420 M	420 M	398 M	398 M	417 M	417 M	528 M	528 M
Gross Profit Ratio	-	-	-	-	0.536	0.547	0.566	0.53	0.632	0.618	0.642	0.642	0.437	0.555	0.596	0.502	0.52	0.448	0.455	0.584	0.668	0.546	0.546	0.635	0.665	0.541	0.541	0.514	0.514	0.534	0.534	0.611	0.611
General and Administrative Expenses	135 M	137 M	113 M	133 M	81 M	70.6 K	43.8 K	-	-	63 M	57.3 M	-	-	64.6 M	71.5 M	-35.6 M	73 M	90.6 M	92.7 M	85.5 M	68.3 M	11.9 M	11.9 M	91.3 M	31.6 M	78.2 M	78.2 M	75 M	75 M	79.9 M	79.9 M	76.9 M	76.9 M
Selling And Marketing Expenses	-	-	-	-	61.1 M	33.1 K	32.6 K	-	-	60.8 M	67.8 M	-	-	92.7 M	103 M	149 M	113 M	96.8 M	55.2 M	173 M	198 M	143 M	143 M	238 M	68.8 M	192 M	192 M	166 M	166 M	184 M	184 M	258 M	258 M
Selling General And Administrative Expenses	-	-	-	-	146 M	111 K	153 M	140 M	121 M	127 M	127 M	174 M	124 M	190 M	181 M	108 M	192 M	189 M	167 M	406 M	283 M	155 M	155 M	344 M	106 M	270 M	270 M	241 M	241 M	264 M	264 M	335 M	335 M
Other Expenses	-	-	-	-	-345 K	-	488 K	826 K	662 K	18.6 M	4.4 M	-8.65 M	4.92 M	18.2 M	-	-58.1 M	20.8 M	6.22 M	-12.1 M	-177 M	-9.03 M	96.5 M	96.5 M	-31.2 M	13.9 M	-26.2 M	-26.2 M	-23.4 M	-23.4 M	-118 M	-118 M	-44.3 M	-44.3 M
Operating Expenses	156 M	143 M	145 M	139 M	146 M	115 K	152 M	139 M	120 M	146 M	131 M	183 M	119 M	208 M	181 M	255 M	213 M	196 M	155 M	230 M	276 M	258 M	258 M	313 M	121 M	274 M	274 M	247 M	247 M	155 M	155 M	300 M	300 M
Cost And Expenses	-	-	-	-	273 M	233 K	283 M	277 M	234 M	260 M	209 M	298 M	308 M	379 M	339 M	448 M	431 M	423 M	413 M	458 M	414 M	550 M	550 M	546 M	204 M	630 M	630 M	623 M	623 M	518 M	518 M	636 M	636 M
Interest Expense	-	-	-	-	-	-	-	569 K	424 K	-	-	424 M	2.39 B	-	-	23.5 M	-	-	-	-	-	47.2 M	47.2 M	-	-	44.8 M	44.8 M	46.8 M	46.8 M	57.9 M	57.9 M	22 M	22 M
Depreciation And Amortization	-	-	-	-	10.3 M	6.4 K	10.4 M	6.89 M	9.01 M	10.5 M	9.9 M	1.92 M	16.2 M	8.29 M	21.6 M	11.2 M	15.3 M	17.9 M	10.7 M	28.9 M	31.8 M	4.87 M	4.87 M	18.6 M	8.39 M	-25.6 M	-25.6 M	-22 M	-22 M	1.1 M	1.1 M	-2.27 M	-2.27 M
EBITDA	-45 M	17 M	-229 M	-37 M	11.2 M	34.4 K	28.8 M	23.3 M	89.1 M	65.9 M	18.6 M	25.3 M	44 M	18.2 M	72.1 M	-24.3 M	60 M	13.4 M	58.8 M	-71.6 M	8.19 M	92.6 M	92.6 M	108 M	53.6 M	126 M	126 M	129 M	129 M	285 M	285 M	226 M	226 M
EBITDA Ratio	-0.177	0.064	-0.898	-0.145	0.041	0.133	0.096	0.079	0.271	0.221	0.085	0.079	0.131	0.047	0.185	-0.079	0.132	0.032	0.124	-0.13	0.02	0.144	0.144	0.169	0.215	0.162	0.162	0.167	0.167	0.366	0.366	0.262	0.262
Operating Income	-47 M	8 M	-238 M	-48 M	909 K	28 K	18.4 M	16.4 M	74.7 M	39.1 M	8.82 M	23.3 M	27.8 M	5.91 M	50.5 M	-70.4 M	23.9 M	-10.7 M	60.2 M	90.6 M	1.31 M	91.8 M	91.8 M	92.4 M	45.3 M	145 M	145 M	151 M	151 M	262 M	262 M	228 M	228 M
Operating Income Ratio	-0.185	0.03	-0.933	-0.188	0.003	0.108	0.061	0.056	0.242	0.131	0.04	0.073	0.083	0.015	0.13	-0.056	0.053	-0.026	0.127	0.165	0.003	0.143	0.143	0.145	0.182	0.188	0.188	0.195	0.195	0.336	0.336	0.264	0.264
Income Before Tax	-	-	-	-	6.7 M	32.8 K	27.1 M	34.9 M	79.6 M	42 M	15.1 M	28.6 M	52.2 M	17.4 M	29.4 M	-65 M	38.2 M	-16 M	-118 M	-32.5 M	-73.6 M	40.6 M	40.6 M	21.4 M	-79.1 M	75 M	75 M	82.5 M	82.5 M	205 M	205 M	204 M	204 M
Income Before Tax Ratio	-	-	-	-	0.024	0.126	0.09	0.119	0.258	0.141	0.069	0.089	0.155	45.1	75.5	-0.033	0.084	-0.039	-0.25	-0.059	-0.177	0.063	0.063	0.034	-0.317	0.097	0.097	0.107	0.107	0.263	0.263	0.236	0.236
Income Tax Expense	-	-	-	-	2.49 M	7.44 K	10.2 M	8.79 M	17.3 M	15.5 M	6.78 M	20.6 M	-5.06 M	24.7 M	11.8 M	-14.3 M	3.68 M	19.1 M	-24.5 M	46.5 M	-66.4 M	11.4 M	11.4 M	10.5 M	4.87 M	18.9 M	18.9 M	17.7 M	17.7 M	22.9 M	22.9 M	52.9 M	52.9 M
Net Income Ratio	-0.291	0.011	-0.855	-0.117	0.015	0.103	0.052	0.097	0.202	0.098	0.037	0.023	0.169	-0.024	0.052	-0.032	0.075	-0.083	-0.225	-0.144	-0.098	0.045	0.045	0.016	-0.335	0.082	0.082	0.105	0.105	0.24	0.24	0.175	0.175
Earnings Per Share, EPS	-0.81	0.03	-2.38	-0.33	0.046	0.0	0.17	0.31	0.68	0.32	0.09	0.083	0.63	-0.1	0.22	-0.67	0.38	-0.38	-1.16	-0.86	-0.44	0.315	0.315	0.113	-0.91	0.7	0.7	0.89	0.89	2.04	2.04	16.5 K	16.5 K
EPS Diluted	-0.81	0.03	-2.38	-0.33	0.046	0.0	0.17	0.31	0.68	0.32	0.09	0.083	0.63	-0.1	0.22	-0.67	0.38	-0.38	-1.16	-0.86	-0.44	0.315	0.315	0.113	-0.91	0.7	0.7	0.89	0.89	2.04	2.04	16.5 K	16.5 K
Weighted Average Shares Outstanding	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.4 M	91.5 M	91.5 M	91.5 M	93.6 M	89.4 M	91.5 M	90.5 M	92.5 M	90.5 M	90.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	9.15 K	9.15 K

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Завод ДИОД (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

How much revenue the company earned
How much it spent on production, personnel, marketing, taxes, etc.
What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features

The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Applied Therapeutics APLT	-	-	$ 8.42 M	USA
ESSA Pharma EPIX	-	-	$ 8.86 M	Canada
Generation Bio Co. GBIO	-	-	$ 344 M	USA
Clearside Biomedical CLSD	-	-	$ 25.3 M	USA
Merus N.V. MRUS	-	-	$ 5.78 B	Niderland
RAPT Therapeutics RAPT	-	-	$ 2.36 B	USA
Annexon ANNX	$ 4.21	4.99 %	$ 653 M	USA
AbbVie ABBV	$ 291.22	1.06 %	$ 515 B	USA
22nd Century Group XXII	$ 1.56	-19.17 %	$ 287 K	USA
Axon Enterprise AXON	$ 313.68	-18.01 %	$ 24.5 B	USA
Biogen BIIB	$ 248.51	1.88 %	$ 36.4 B	USA
BioLineRx Ltd. BLRX	$ 1.73	-2.15 %	$ 4.26 B	Israel
Theratechnologies THTX	-	-	$ 83.9 M	Canada
Exelixis EXEL	$ 69.55	1.22 %	$ 18.9 B	USA
Geron Corporation GERN	$ 0.99	3.97 %	$ 660 M	USA
Gilead Sciences GILD	$ 166.9	-0.4 %	$ 208 B	USA
Grifols, S.A. GRFS	$ 8.46	-0.12 %	$ 5.75 B	Spain
Alnylam Pharmaceuticals ALNY	$ 155.97	-0.44 %	$ 20.4 B	USA
InflaRx N.V. IFRX	$ 1.31	-3.69 %	$ 88.1 M	Germany
INmune Bio INMB	$ 1.12	-4.68 %	$ 27.7 M	USA
Insmed Incorporated INSM	$ 114.55	5.32 %	$ 22.8 B	USA
Johnson & Johnson JNJ	$ 274.89	0.95 %	$ 662 B	USA
Titan Pharmaceuticals TTNP	-	-3.76 %	$ 3.47 M	USA
Lineage Cell Therapeutics LCTX	$ 1.02	3.75 %	$ 235 M	USA
BioVie BIVI	$ 1.33	9.92 %	$ 1.96 M	USA
Longeveron LGVN	$ 1.82	6.43 %	$ 32 B	USA
Allena Pharmaceuticals ALNA	-	3.16 %	$ 1.9 M	USA
TCR2 Therapeutics TCRR	-	-	$ 58.1 M	USA
Crinetics Pharmaceuticals CRNX	$ 84.95	0.13 %	$ 7.99 B	USA
Mustang Bio MBIO	$ 0.39	0.15 %	$ 1.91 M	USA
TFF Pharmaceuticals TFFP	-	-60.05 %	$ 125 K	USA
Can-Fite BioPharma Ltd. CANF	$ 1.63	1.87 %	$ 2.68 M	Israel
Mesoblast Limited MESO	$ 14.26	1.13 %	$ 17.2 B	Australia
Mirum Pharmaceuticals MIRM	$ 93.81	0.28 %	$ 4.71 B	USA
Adaptimmune Therapeutics plc ADAP	-	-15.15 %	$ 60.3 M	Britain
AVEO Pharmaceuticals AVEO	-	-	$ 521 M	USA
Codexis CDXS	$ 1.09	6.37 %	$ 95 M	USA
MannKind Corporation MNKD	$ 3.91	4.0 %	$ 1.2 B	USA
MediciNova MNOV	$ 1.44	-0.69 %	$ 70.7 M	USA
Axcella Health AXLA	-	-16.42 %	$ 249 M	USA
Merck & Co. MRK	$ 146.81	-0.07 %	$ 367 B	USA
Dynavax Technologies Corporation DVAX	-	-	$ 2.02 B	USA
Tyme Technologies TYME	-	8.07 %	$ 54 M	USA
Curis CRIS	$ 0.88	3.67 %	$ 11.6 M	USA
Cyclerion Therapeutics CYCN	$ 34.99	3.77 %	$ 147 M	USA
CorMedix CRMD	$ 5.31	1.43 %	$ 383 K	USA
Novartis AG NVS	$ 162.64	0.44 %	$ 315 B	Schweiz
CRISPR Therapeutics AG CRSP	$ 50.09	3.15 %	$ 4.5 B	Schweiz

Завод ДИОД Income Statement 2025-2007 | DIOD

Brief overview of financial results at Завод ДИОД

What the figures show

Annual Income Statement Завод ДИОД

Revenue

Cost Of Revenue

Gross Profit

Gross Profit Ratio

General and Administrative Expenses

Selling And Marketing Expenses

Selling General And Administrative Expenses

Other Expenses

Operating Expenses

Cost And Expenses

Interest Expense

Depreciation And Amortization

EBITDA

EBITDA Ratio

Operating Income

Operating Income Ratio

Income Before Tax

Income Before Tax Ratio

Income Tax Expense

Net Income Ratio

Earnings Per Share, EPS

EPS Diluted

Weighted Average Shares Outstanding

Annual performance